Scheen A. J, & Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab. 40, 176-185 (2014).
Scheen A. J. Cardiovascular effects of gliptins. Nat. Rev. Cardiol. 10, 73-84 (2013).
Pfeffer M. A, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247-2257 (2015).
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128 (2015).
Wanner C, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1515920 (2016).
Fitchett D, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME? trial. Eur. Heart J. 37, 1526-1534 (2016).
Marso S. P, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. http://.dx.doi.org/10.1056/NEJMoa1603827 (2016).
Scheen A. J. Pharmacodynamics, efficacy and safety of sodium-glucose co transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75, 33-59 (2015).
Scheen A. J. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis. Diabetes Metab. 42, 71-76 (2016).
Ferrannini E, et al. Shift to fatty substrates utilization in response to sodium-glucose co transporter 2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes 65, 1190-1195 (2016).
